title: [Non-alcoholic fatty liver disease: age peculiarities, breakthrough in pathogenetic therapy].
abstract: Non-alcoholic fatty liver disease, including non-alcoholic steatohepatosis (NSH) and non-alcoholic steatohepatitis (NASH) is considered to be a wide spread disease. Such reasons as metabolic, toxic, infections, alimentary and cryptogenic cause this disease. Pathogenesis of the disease is complex. If the necessary medical preventive measures are absent the disease develops as follows, first steatosis, then steatohepatitis, fibrosis, liver cirrhosis, hepatocarcinoma. The aim of the investigation was to study influence of Metadoxil in patients with NSH and NASH. The conducted investigation have shown high efficiency of the drug at combined treatment of a patient.
authors.forename: A I
authors.initials: AI
authors.lastname: Pal'tsev
authors.forename: I V
authors.initials: IV
authors.lastname: Sharapov
authors.forename: E N
authors.initials: EN
authors.lastname: Gorbunova
authors.forename: T N
authors.initials: TN
authors.lastname: Khomchenko
authors.forename: I V
authors.initials: IV
authors.lastname: Kurganova
authors.forename: G S
authors.initials: GS
authors.lastname: Soldatova
authors.forename: A A
authors.initials: AA
authors.lastname: Eremina
authors.forename: Iu A
authors.initials: IuA
authors.lastname: Nikolaev
mesh_terms: D000328:Adult; D000368:Aged; D000375:Aging / Q000378:metabolism / Q000473:pathology; D004338:Drug Combinations; D005234:Fatty Liver / Q000175:diagnosis* / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008875:Middle Aged; D011736:Pyridoxine / Q000008:administration & dosage / Q000627:therapeutic use*; D011761:Pyrrolidonecarboxylic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; C037845:metadoxine; D011736:Pyridoxine; D011761:Pyrrolidonecarboxylic Acid